PMID- 25044137
OWN - NLM
STAT- MEDLINE
DCOM- 20141216
LR  - 20181202
IS  - 1724-6016 (Electronic)
IS  - 1120-6721 (Linking)
VI  - 24
IP  - 6
DP  - 2014 Nov-Dec
TI  - Effect of anti-VEGF treatment on choroidal thickness over time in patients with 
      neovascular age-related macular degeneration.
PG  - 897-903
LID - 10.5301/ejo.5000509 [doi]
AB  - PURPOSE: To evaluate change in subfoveal choroidal thickness (SCT) as measured by 
      spectral-domain optical coherence tomography (SD-OCT) in patients with 
      neovascular age-related macular degeneration (NVAMD) undergoing anti-vascular 
      endothelial growth factor (VEGF) therapy. METHODS: Patients with a diagnosis of 
      NVAMD were retrospectively reviewed to identify those who had at least 12 months 
      of follow-up. The SCT was manually measured from Bruch membrane to the 
      choroid-sclera junction at baseline and last follow-up. Only cases in which the 
      choroid was fully visible were included in quantitative analyses. The SCT 
      measurements were correlated with other characteristics including number and 
      duration of treatments. RESULTS: Sixty eyes of 47 patients with a follow-up of 
      23.8 months (SD 7.3) met study inclusion criteria, and 49 eyes of 40 patients 
      received anti-VEGF treatment. Mean age was 83.7 years, and 52% were female. 
      Treated eyes received a mean of 7.8 (SD 7.3) intravitreal anti-VEGF injections. 
      The SCT at baseline was 126.7 mum (SD 50.6) for untreated and 136.2 mum (SD 57.6) 
      for treated eyes. The SCT showed a decrease over time in both groups, with a mean 
      rate of reduction of 6.0 mum (p<0.0002) in treated eyes and 3.6 mum (p = 0.3741) 
      in untreated eyes. However, the change in SCT did not differ between the groups 
      (p = 0.5113), and did not correlate with the number of re-treatments (p = 0.552), 
      visual acuity at baseline (p = 0.618), or change in visual acuity over time (p = 
      0.429). CONCLUSIONS: Although choroidal thickness decreased over time in eyes 
      with NVAMD, anti-VEGF therapy did not appear to accelerate or otherwise alter 
      this decline.
FAU - McDonnell, Emma C
AU  - McDonnell EC
AD  - Doheny Eye Institute, affiliate of Stein Eye Institute and the University of 
      California, Los Angeles - USA.
FAU - Heussen, Florian M
AU  - Heussen FM
FAU - Ruiz-Garcia, Humberto
AU  - Ruiz-Garcia H
FAU - Ouyang, Yanling
AU  - Ouyang Y
FAU - Narala, Ramsudha
AU  - Narala R
FAU - Walsh, Alexander C
AU  - Walsh AC
FAU - Sadda, Srinivas R
AU  - Sadda SR
LA  - eng
GR  - EY03040/EY/NEI NIH HHS/United States
GR  - R01 EY014375/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140718
PL  - United States
TA  - Eur J Ophthalmol
JT  - European journal of ophthalmology
JID - 9110772
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Choroid/*pathology
MH  - Female
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Degeneration/drug therapy
MH  - Male
MH  - Organ Size
MH  - Retrospective Studies
MH  - Time Factors
MH  - Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
MH  - Visual Acuity/physiology
MH  - Wet Macular Degeneration/diagnosis/*drug therapy/physiopathology
EDAT- 2014/07/22 06:00
MHDA- 2014/12/17 06:00
CRDT- 2014/07/22 06:00
PHST- 2014/06/19 00:00 [accepted]
PHST- 2014/07/22 06:00 [entrez]
PHST- 2014/07/22 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - C4A38460-CF55-4F66-BC6A-3DA2C41ED3BA [pii]
AID - 10.5301/ejo.5000509 [doi]
PST - ppublish
SO  - Eur J Ophthalmol. 2014 Nov-Dec;24(6):897-903. doi: 10.5301/ejo.5000509. Epub 2014 
      Jul 18.